INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

The Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants

Show full item record

Bookmark or cite this item:

Files in this item

File Description Format
PDF Pharmacotherapy ... macogenomics_6_29_2011.pdf (214KB) (no description provided) PDF
Title: The Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants
Author(s): Cavallari, Larisa H.; Shin, Jaekyu; Perera, Minoli A.
Subject(s): warfarin polymorphism dabigatran genotype pharmacogenetics
Abstract: Warfarin is the most commonly prescribed oral anticoagulant. However, it remains a difficult drug to manage mostly because of its narrow therapeutic index and wide inter-patient variability in anticoagulant effects. Over the past decade, there has been substantial progress in our understanding of genetic contributions to variable warfarin response, particularly in regard to warfarin dose requirements. The genes encoding for cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1) are the major genetic determinants of warfarin pharmacokinetics and pharmacodynamics, respectively. Numerous studies have demonstrated significant contributions of these genes to warfarin dose requirements. The CYP2C9 gene has also been associated with bleeding risk with warfarin. The CYP4F2 gene influences vitamin K availability and makes minor contributions to warfarin dose requirements. Less is known about genes influencing warfarin response in African Americans compared to other racial groups, but this is the focus of on-going research. Several warfarin pharmacogenetic dosing algorithms and FDA-cleared genotyping tests are available for clinical use. Clinical trials are on-going to determine the clinical utility and cost effectiveness of genotype-guided warfarin dosing. Results from these trials will likely influence clinical uptake and third party payer reimbursement for genotype-guided warfarin therapy. Currently, there is a lack of pharmacogenetic data with the newly approved oral anticoagulant, dabigatran, and with other oral anticoagulants in the research and development pipeline.
Issue Date: 2011-12
Publisher: IOS Press
Citation Info: Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy. 2011 Dec;31(12):1192-207. DOI: 10.1592/phco.31.12.1192
Type: Article
Description: This is a copy of an article published in the journal Pharmacotherapy © 2011 IOS Press. DOI 10.1592/phco.31.12.1192
ISSN: 0277-0008
Sponsor: American Heart Association, Midwest Affiliate Grant-In-Aid (10GRNT3750024) to L.H.C., American Heart Association, Midwest Affiliate Clinical Research Program Award (10CRP3740026) and NIH NHLBI award (1 K23 HL089808-01A2) to M.P.
Date Available in INDIGO: 2012-05-27

This item appears in the following Collection(s)

Show full item record


Country Code Views
United States of America 442
China 212
Russian Federation 32
United Kingdom 22
Germany 12


My Account


Access Key